Description: Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).
Home Page: www.entradatx.com
TRDA Technical Analysis
6 Tide Street
Boston,
MA
02210
United States
Phone:
857 520 9158
Officers
| Name | Title |
|---|---|
| Mr. Dipal Doshi | Pres, CEO & Director |
| Mr. Nathan J. Dowden | Chief Operating Officer |
| Dr. Natarajan Sethuraman Ph.D. | Chief Scientific Officer |
| Mr. Kory James Wentworth CPA | CFO & Treasurer |
| Dr. Jared Cohen J.D., Ph.D. | Gen. Counsel |
| Ms. Kerry Robert M.S. | VP of People |
| Dr. Nerissa C. Kreher M.B.A., M.D., M.S. | Chief Medical Officer |
| Ms. Karla MacDonald | Chief Corp. Affairs Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.568 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-10-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 124 |